These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 34808619)

  • 1. The Effect of Interferon-Beta Therapy on T-Helper 17/miR-326 and T-Helper 1/miR-29b-3p Axis in Relapsing-Remitting Multiple Sclerosis Patients.
    Karimi L; Eskandari N; Shaygannejad V
    Neuroimmunomodulation; 2022; 29(3):177-185. PubMed ID: 34808619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Expression Levels of miR-29b-3p and miR-326 in T Helper-1 and T Helper-17 Cells Isolated from Responsive and Non-responsive Relapsing-remitting Multiple Sclerosis Patients Treated with Interferon-beta.
    Karimi L; Eskandari N; Shaygannejad V; Zare N; Andalib A; Khanahmad H; Mirmosayyeb O
    Iran J Allergy Asthma Immunol; 2020 Aug; 19(4):416-425. PubMed ID: 33463108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
    Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
    Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
    Bălaşa R; Bajko Z; Huţanu A
    Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.
    Axtell RC; de Jong BA; Boniface K; van der Voort LF; Bhat R; De Sarno P; Naves R; Han M; Zhong F; Castellanos JG; Mair R; Christakos A; Kolkowitz I; Katz L; Killestein J; Polman CH; de Waal Malefyt R; Steinman L; Raman C
    Nat Med; 2010 Apr; 16(4):406-12. PubMed ID: 20348925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
    Nischwitz S; Faber H; Sämann PG; Domingues HS; Krishnamoorthy G; Knop M; Müller-Sarnowski F; Yassouridis A; Weber F
    Acta Neurol Scand; 2014 Jul; 130(1):46-52. PubMed ID: 24571587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus-encoded BART9 and BART15 miRNAs are elevated in exosomes of cerebrospinal fluid from relapsing-remitting multiple sclerosis patients.
    Mohammadinasr M; Montazersaheb S; Hosseini V; Kahroba H; Talebi M; Molavi O; Ayromlou H; Hejazi MS
    Cytokine; 2024 Jul; 179():156624. PubMed ID: 38692184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher expression of IL-12Rβ2 is associated with lower risk of relapse in relapsing-remitting multiple sclerosis patients on interferon-β1b therapy during 3-year follow-up.
    Milosevic E; Dujmovic I; Markovic M; Mesaros S; Rakocevic G; Drulovic J; Mostarica Stojkovic M; Popadic D
    J Neuroimmunol; 2015 Oct; 287():64-70. PubMed ID: 26439963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-27a and miR-214 exert opposite regulatory roles in Th17 differentiation via mediating different signaling pathways in peripheral blood CD4+ T lymphocytes of patients with relapsing-remitting multiple sclerosis.
    Ahmadian-Elmi M; Bidmeshki Pour A; Naghavian R; Ghaedi K; Tanhaei S; Izadi T; Nasr-Esfahani MH
    Immunogenetics; 2016 Jan; 68(1):43-54. PubMed ID: 26563334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Connection of miR-185 and miR-320a expression levels with response to interferon-beta in multiple sclerosis patients.
    Mousavi SR; Tahmasebivand M; Khorrami M; Ayromlou H; Khalili SK; Khorvash F; Rikhtegar R; Khademi B; Bahmanpour Z; Emamalizadeh B
    Mult Scler Relat Disord; 2020 Sep; 44():102264. PubMed ID: 32554287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in circulating T cell functional subpopulations in interferon-beta treated multiple sclerosis patients: A pilot study.
    Monteiro A; Rosado P; Rosado L; Fonseca AM; Paiva A
    J Neuroimmunol; 2020 Feb; 339():577113. PubMed ID: 31778850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inverse Relation between MxA Gene Expression and Age in Multiple Sclerosis Patients Reveals a Gender Difference in Response to Interferon Therapy.
    Taheri M; Mirinezhad M; Omrani MD; Sajjadi E; Inoko H; Sayad A
    Iran J Allergy Asthma Immunol; 2017 Feb; 16(1):21-27. PubMed ID: 28417621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells.
    Sweeney CM; Lonergan R; Basdeo SA; Kinsella K; Dungan LS; Higgins SC; Kelly PJ; Costelloe L; Tubridy N; Mills KH; Fletcher JM
    Brain Behav Immun; 2011 Aug; 25(6):1170-81. PubMed ID: 21420486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Effect of Interferon Beta and Natalizumab on miR-20b Expression in Patients with Relapsing-Remitting Multiple Sclerosis is Potentially Mediated by Modulation of the Jak-STAT Signaling Pathway: A Case-control Study.
    Jafari Harandi A; Mirzaee Sedigh A; Ataei M; Bayrami S; Esmaeilzadeh E; Sanati MH
    Iran J Immunol; 2024 Jun; 21(2):158-165. PubMed ID: 38761094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].
    Zhang X; Zhang Q; Shi X; Yin R; Zhang Z; Hou X
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jul; 29(7):751-3. PubMed ID: 23837989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
    Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
    J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-141 and miR-200a, Revelation of New Possible Players in Modulation of Th17/Treg Differentiation and Pathogenesis of Multiple Sclerosis.
    Naghavian R; Ghaedi K; Kiani-Esfahani A; Ganjalikhani-Hakemi M; Etemadifar M; Nasr-Esfahani MH
    PLoS One; 2015; 10(5):e0124555. PubMed ID: 25938517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.
    Fattahi M; Eskandari N; Sotoodehnejadnematalahi F; Shaygannejad V; Kazemi M
    Cell J; 2020 Apr; 22(1):92-95. PubMed ID: 31606972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.